TY - JOUR
T1 - Prognostic factors in decision‐making in the clinical management of Hodgkin's disease
AU - Hagemeister, Fredrick B.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1988
Y1 - 1988
N2 - At the beginning of this conference, Dr Ford asked whether or not Hodgkin's disease was a malignancy. Most physicians would agree that, regardless of whether this question can be answered on a molecular level, Hodgkin's disease certainly behaves like a malignancy, and clinically fits criteria necessary to call it one. It grows without control locally, comprising vital organs. It ‘metastasizes’, infiltrates organs, and causes organ dysfunction. Patients afflicted with the disease have a shortened life span without proper therapy, as demonstrated by DeVita in his original publication describing the benefits of MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine, prednisone) (DeVita et al., 1970). However, it can progress very slowly, with 50 per cent of untreated patients with stage III or IV disease dead at one year, but 10 to 15 per cent alive at five years. Therefore, in its clinical behaviour, Hodgkin's disease certainly qualifies as a malignant disorder, despite the fact that we do not have the molecular means of calling it one.
AB - At the beginning of this conference, Dr Ford asked whether or not Hodgkin's disease was a malignancy. Most physicians would agree that, regardless of whether this question can be answered on a molecular level, Hodgkin's disease certainly behaves like a malignancy, and clinically fits criteria necessary to call it one. It grows without control locally, comprising vital organs. It ‘metastasizes’, infiltrates organs, and causes organ dysfunction. Patients afflicted with the disease have a shortened life span without proper therapy, as demonstrated by DeVita in his original publication describing the benefits of MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine, prednisone) (DeVita et al., 1970). However, it can progress very slowly, with 50 per cent of untreated patients with stage III or IV disease dead at one year, but 10 to 15 per cent alive at five years. Therefore, in its clinical behaviour, Hodgkin's disease certainly qualifies as a malignant disorder, despite the fact that we do not have the molecular means of calling it one.
KW - Clinical Management
KW - Hodgkin's disease
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=0023722307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023722307&partnerID=8YFLogxK
U2 - 10.1002/hon.2900060309
DO - 10.1002/hon.2900060309
M3 - Article
C2 - 3042583
AN - SCOPUS:0023722307
SN - 0278-0232
VL - 6
SP - 257
EP - 269
JO - Hematological Oncology
JF - Hematological Oncology
IS - 3
ER -